Saturday 17 October 2026
Export OGEN’s income statement to Excel — free account
Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022. In the quarter to June 2026, EPS grew 81.6% and free cash flow fell 66.4%, each against the same quarter a year earlier.
0.43
0.01
−2.27%
Follow OGEN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 2 | — | — |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
P/S ratio |
— | — | — | — | — | 60.08 | 66.13 | 123.16 | — | — |
Altman Z-Score |
— | — | — | — | — | 8.80 | (15.24) | (67.30) | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (1.49) | (34.10) | (159.07) | — | — |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | — | — | — | (21.09) | (5.94) | (13.82) | — | — |
P/B ratio |
— | — | — | — | — | 2.20 | 1.27 | 9.67 | — | — |
Price to Tangible BV |
— | — | — | — | — | 2.20 | 1.27 | 9.67 | — | — |
EV/Sales |
— | — | — | — | — | 31.57 | 24.82 | 114.40 | — | — |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | — | — | — | (2.04) | (0.36) | (1.94) | — | — |
EV/FCF |
— | — | — | — | — | (2.04) | (0.35) | (1.95) | — | — |
Quick Ratio |
3.04 | 6.86 | 17.31 | 9.87 | 13.14 | 18.87 | 7.16 | 1.94 | 0.51 | 4.73 |
Current Ratio |
3.14 | 8.01 | 18.78 | 10.18 | 13.40 | 19.17 | 8.95 | 2.15 | 0.87 | 5.64 |
Net Debt/EBITDA |
0.48 | 0.93 | 2.03 | 1.16 | 0.66 | 1.73 | 0.79 | 0.17 | 0.08 | 0.98 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.83 | 0.95 | 0.80 | 0.84 | 0.64 | 0.86 | 1.07 | 0.35 | 0.81 | 0.94 |
Capex/Depreciation |
(0.33) | 0.00 | (4.14) | (0.40) | 0.00 | (1.07) | (2.58) | (34.17) | — | 0.00 |
Interest Coverage |
(2,083.54) | (31.06) | (1,723.12) | (2,175.01) | (2,489.86) | (998.16) | (955.02) | (683.17) | (354.32) | (11.91) |
| (220.80%) | (452.93%) | (153.18%) | (122.09%) | (259.28%) | (93.80%) | (81.08%) | (317.98%) | (1,550.11%) | (243.94%) | |
| (168.47%) | (116.83%) | (77.41%) | (74.47%) | (137.54%) | (66.98%) | (66.47%) | (209.44%) | (328.26%) | (170.58%) | |
ROIC |
0.00% | (2,795.56%) | (927.17%) | 0.00% | 0.00% | 0.00% | (569.54%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(286.51%) | (106.57%) | (54.24%) | (91.14%) | (158.43%) | (59.72%) | (111.50%) | (999.02%) | 4,987.21% | (118.85%) |
Average Days of Receivables |
— | — | — | — | — | 29.37 | 0.00 | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12,167.93% | 7,659.85% | 41,089.12% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6,059.66% | 3,406.54% | 14,461.54% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,940.23% | 564.41% | 2,697.08% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | 0.50 | 0.87 | 0.14 | — | — |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
Earnings Yield |
— | — | — | — | — | (31.08%) | (95.46%) | (136.57%) | — | — |
Free Cash Flow Yield |
— | — | — | — | — | (25.81%) | (106.18%) | (47.71%) | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34 | 1.97 | 0.50 | 0.00 | 0.00 |
Operating CF per Share |
(2,830.04) | (2,357.00) | (1,243.81) | (553.74) | (539.90) | (208.19) | (227.63) | (97.34) | (38.90) | (4.29) |
Capex per Share |
(10.00) | 0.00 | (17.08) | (1.07) | 0.00 | (0.68) | (1.73) | (12.50) | 0.00 | 0.00 |
Free Cash Flow per Share |
(2,840.04) | (2,357.00) | (1,260.89) | (554.81) | (539.90) | (208.87) | (229.36) | (109.84) | (38.90) | (4.29) |
Cash per Share |
1,632.24 | 2,283.74 | 2,768.26 | 777.36 | 561.77 | 421.42 | 170.80 | 46.51 | 3.91 | 3.89 |
Shareholders Equity per Share |
1,186.28 | 2,339.37 | 2,860.55 | 733.26 | 536.45 | 409.37 | 194.46 | 42.30 | (0.96) | 3.84 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1,186.28 | 2,339.37 | 2,860.55 | 733.26 | 536.45 | 409.37 | 194.46 | 42.30 | (0.96) | 3.84 |
Free Cash Flow |
(7.10) | (6.36) | (9.20) | (13.04) | (16.95) | (13.51) | (15.34) | (8.23) | (8.60) | (9.25) |
Working Capital |
2.88 | 6.29 | 20.77 | 16.99 | 16.64 | 26.26 | 12.69 | 2.07 | (0.21) | 8.28 |
Capital Expenditures |
(0.02) | — | (0.12) | (0.03) | — | (0.04) | (0.12) | (0.94) | — | — |
Net Current Asset Value |
2.88 | 6.29 | 20.77 | 16.32 | 16.15 | 25.96 | 12.54 | 2.07 | (0.21) | 8.28 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | — | 0.50 | 0.88 | 24.84 | — | — |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.86 | 3.03 | 0.26 | 0.68 | 1.21 | 0.90 | 0.37 | 0.00 | — | 0.00 |
Cash ROIC |
(100.76%) | (50.98%) | (22.40%) | (36.73%) | (49.16%) | (25.14%) | (62.79%) | (123.69%) | (1,316.80%) | (55.43%) |
Accounts Receivable Turnover |
— | — | — | — | — | 7.70 | 0.00 | 0.00 | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | — | — | — | 0.01 | — | — | — | 0.03 |
Average Payables |
1.05 | 1.05 | 0.93 | 1.29 | 1.24 | 0.94 | 1.04 | 1.30 | 1.42 | 1.46 |
Average Assets |
5.04 | 5.76 | 14.63 | 20.90 | 19.22 | 23.46 | 21.49 | 9.86 | 3.22 | 5.77 |
Average Common Equity |
3.85 | 1.49 | 7.39 | 12.75 | 10.19 | 16.75 | 17.62 | 6.50 | 0.68 | 4.03 |
Columns are period end dates